Infant Bacterial Therapeutics AB (FRA:9IB) Interest Expense: €0.00 Mil (TTM As of Mar. 2026)

What is Infant Bacterial Therapeutics AB Interest Expense?

Infant Bacterial Therapeutics AB FRA:9IB +0.48% 13 Interest Expense is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:9IB with a GF Score™ of 13/100. The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Infant Bacterial Therapeutics AB's interest expense for the three months ended in Mar. 2026 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Infant Bacterial Therapeutics AB's Operating Income for the three months ended in Mar. 2026 was € -2.18 Mil. Infant Bacterial Therapeutics AB's Interest Expense for the three months ended in Mar. 2026 was € 0.00 Mil. Infant Bacterial Therapeutics AB has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Infant Bacterial Therapeutics AB (FRA:9IB) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Infant Bacterial Therapeutics AB's Interest Expense for the three months ended in Mar. 2026 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-2.18 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €0.00 Mil.

Infant Bacterial Therapeutics AB's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Infant Bacterial Therapeutics AB had no long-term debt ⁽¹⁾.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Infant Bacterial Therapeutics AB has no debt.

Infant Bacterial Therapeutics AB Interest Expense Historical Data

* Premium members only.

The historical data trend for Infant Bacterial Therapeutics AB's Interest Expense can be seen below:

Infant Bacterial Therapeutics AB Interest Expense Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-0.04

-0.03

0.00

Infant Bacterial Therapeutics AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

13GF Score

Infant Bacterial Therapeutics AB FRA:9IB

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Infant Bacterial Therapeutics AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of €0.00 Mil mean?

Infant Bacterial Therapeutics AB (FRA:9IB) has a Interest Expense of €0.00 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Infant Bacterial Therapeutics AB and its competitors.

Is Infant Bacterial Therapeutics AB's Interest Expense too high?

Infant Bacterial Therapeutics AB's current Interest Expense is €0.00 Mil. Overall, Infant Bacterial Therapeutics AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.

How does Infant Bacterial Therapeutics AB's Interest Expense compare to VRTX and REGN?

Infant Bacterial Therapeutics AB's Interest Expense of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Infant Bacterial Therapeutics AB and its competitors. Infant Bacterial Therapeutics AB's current Interest Expense is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Infant Bacterial Therapeutics AB stock overvalued right now?

Infant Bacterial Therapeutics AB (FRA:9IB) has a current Interest Expense of €0.00 Mil. The current Interest Expense is €0.00 Mil. Infant Bacterial Therapeutics AB's overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Infant Bacterial Therapeutics AB (FRA:9IB), the current Interest Expense is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Infant Bacterial Therapeutics AB Business Description

Industry Healthcare Biotechnology

Comparable Companies OSTO:SYNACT OSTO:MVIR OSTO:XSPRAY OSTO:FLUO OSTO:ONCO XSAT:CESSA OSTO:CANTA OSTO:ALZCUR OSTO:SPRINT OSTO:CLBIO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges IBT B:Sweden

Address Katarina Bangata 70, Stockholm, SWE, 116 42

Website https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

13GF Score

Get the complete analysis for FRA:9IB

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.29

Price

View FRA:9IB Analysis

See Interest Expense data for all stocks →